Search trials



Primary RegistryProtocol numberPublic titleScientific titleType of studyRecruitment statusLast updated
LBCTR2022105089GBT021601-021A Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell DiseaseA Phase 2/3 Randomized, Multicenter Study of GBT021601 Administered Orally to Participants with Sickle Cell Disease and an Open-Label Pharmacokinetics Study in Pediatric Participants with Sickle Cell DiseaseInterventionalPending07/07/2022
LBCTR2022035001CINC424H12201Platform Study of Novel Ruxolitinib Combinations in Myelofibrosis PatientsA Randomized, Open-label, Phase I/II Open Platform Study Evaluating Safety and Efficacy of Novel Ruxolitinib Combinations in Myelofibrosis PatientsInterventionalSuspended14/02/2022
LBCTR2020104622BO40336ALINAA PHASE III, OPEN-LABEL, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ADJUVANT ALECTINIB VERSUS ADJUVANT PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH COMPLETELY RESECTED STAGE IB (TUMORS 4 CM) TO STAGE IIIA ANAPLASTIC LYMPHOMA KINASEPOSITIVE NONSMALL CELL LUNG CANCERInterventionalOther12/10/2020
LBCTR2022105117232SM302Extension Study of Nusinersen (BIIB058) in Participants With Spinal Muscular Atrophy Who Previously Participated in a Study With NusinersenA Long-Term Extension Study of Nusinersen (BIIB058) Administered at Higher Doses in Participants With Spinal Muscular Atrophy Who Previously Participated in an Investigational Study With NusinersenInterventionalRecruiting08/09/2022
LBCTR2019090195GBT440-007Study to Evaluate the Effect of GBT440 in Pediatrics With Sickle Cell DiseaseA Phase 2a, Open-label, Single and Multiple Dose Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Exploratory Treatment Effect of GBT440 in Pediatric Participants With Sickle Cell DiseaseInterventionalRecruiting19/02/2019
LBCTR2022095130CEHDF2040Ergonomics and Mindfulness for preventing musculoskeletal pain and a better quality of lifeEffect of ergonomics and mindfulness on musculoskeletal pain and quality of life for office workers: a randomized controlled trialInterventionalRecruiting19/09/2022
LBCTR2020063513GBT440-038Open-Label Extension of VoxelotorAn Open-Label Extension Study of Voxelotor Administered Orally to Participants with Sickle Cell Disease Who Have Participated in Voxelotor Clinical TrialsInterventionalPending12/06/2020
LBCTR2022055033CMBG453B12203A Study of Sabatolimab in Combination With Azacitidine and Venetoclax in High or Very High Risk MDS ParticipantsA Single-arm, Open-label, Phase II Study of Sabatolimab in Combination With Azacitidine and Venetoclax in Adult Participants With High or Very High Risk Myelodysplastic Syndromes (MDS) as Per IPSS-R CriteriaInterventionalSuspended21/04/2022
LBCTR2020033438MO39171A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL)A PHASE III/IV, SINGLE ARM, MULTICENTER STUDY OF ATEZOLIZUMAB (TECENTRIQ) TO INVESTIGATE LONG-TERM SAFETY AND EFFICACY IN PREVIOUSLY-TREATED PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER (TAIL)InterventionalComplete22/03/2020
LBCTR2019040224CLCZ696B2319Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LCZ696 Followed by a 52-week Study of LCZ696 Compared With Enalapril in Pediatric Patients With Heart Failure- PANORAMAMulticenter, Open-label Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LCZ696 Followed by a 52-week Randomized, Double-blind, Parallel Group, Active-controlled Study to Evaluate the Efficacy and Safety of LCZ696 Compared With Enalapril in Pediatric Patients From 1 Month to < 18 Years of Age With Heart Failure Due to Systemic Left Ventricle Systolic DysfunctionInterventionalComplete07/04/2019
items per page91 - 100 of 169 items